Prenylcysteine methyl
esters that represent the C-terminal structures of prenylated
proteins demonstrate specific substrate-like interactions with
P-glycoprotein (Zhang, L., Sachs, C. W., Fine, R. L., and Casey, P. J. (1994) J. Biol. Chem. 269, 15973-15976). The simplicity of these compounds provides a unique system for probing the structural specificity of
P-glycoprotein substrates. We have further assessed the structural elements of prenylcysteines involved in the interaction with
P-glycoprotein. Carboxyl group methylation, a modification in many prenylated
proteins, plays an essential role of blocking the negative charge at the free carboxylate. Substitution of the methyl
ester with a methyl
amide or simple
amide does not change the ability of the molecule to stimulate
P-glycoprotein ATPase activity, but substitution with a
glycine is not tolerated unless the carboxyl group of
glycine is methylated. The presence of a
nitrogen atom, which is found in many
P-glycoprotein substrates and modifiers, is also essential for prenylcysteines to interact with
P-glycoprotein. The structure at the
nitrogen atom can, however, influence the type of interaction. Acetylation of the free amino group of
prenylcysteine/results in a significant loss in the ability of prenylcysteines to stimulate
P-glycoprotein ATPase activity. Instead, certain acetylated prenylcysteines behave as inhibitors of this activity. In studies using MDR1-transfected human
breast cancer cells, the acetylated
prenylcysteine analogs inhibit
P-glycoprotein-mediated
drug transport and enhance the steady-state accumulation of [3H]
vinblastine, [3H]
colchicine, and [3H]
taxol. These inhibitors do not, however, affect
drug accumulation in parental cells. These studies provide a novel approach for designing
P-glycoprotein inhibitors that could prove effective in reversing the phenotype of multidrug resistance in
tumor cells.